drugset
Drugs / GSK1247446A
last change May 2008 re-read 9 days ago

GSK1247446A

Vaccine

Developed for
influenza
Investigated by
GlaxoSmithKline

Trials 7

today NCT00545025 · Ph 2 NCT00540228 · Ph 2 NCT00385840 · Ph 2 NCT00374842 · Ph 2 NCT00363077 · Ph 2 NCT00321373 · Ph 2 NCT00321763 · Ph 2
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00545025 Oct → Dec 2007 influenza GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT00540228 Oct 2007 → May 2008 influenza GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT00385840 Oct 2006 → Feb 2007 influenza GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT00374842 Oct → Nov 2006 influenza GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT00363077 Oct → Nov 2006 influenza GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT00321373 May → Jul 2006 influenza GlaxoSmithKline Completed No outcome recorded
Phase 2 NCT00321763 Apr → Jul 2006 influenza GlaxoSmithKline Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as GSK1247446A ClinicalTrials.gov intervention name — accepted as the source's own label NCT00545025 ↗
6

NCT00321763 ↗

NCT00374842 ↗

NCT00321373 ↗

NCT00363077 ↗

NCT00385840 ↗

NCT00540228 ↗
Modality Vaccine “received 1 dose of GSK1247446A vaccine adjuvanted with AS03.” NCT00321373 ↗
Route Intramuscular “The vaccine was administered intramuscularly in the deltoid region of the non-dominant arm.” NCT00321373 ↗